Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.73 |
| ▸ | SELL | P14151 | 1/20 | 0.73 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.62 |
| ▸ | SELE | P16581 | 5/20 | 0.61 |
| ▸ | MAG | P20916 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372449 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL13195877 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29405702 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL13978771 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29389517 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29391699 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29407985 | 0.99 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466129 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466139 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL31010809 | 0.96 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702138-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | Inbiose N.V. (BE) | 2026-03-04 | — | — | EP | claimed |
| WO-2025224348-A1 | PRODUCTION OF A MILK OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2025-10-30 | — | — | WO | claimed |
| US-20250258166-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2025-08-14 | — | — | US | claimed |
| EP-4508429-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | Glycanostics s.r.o. (SK) | 2025-02-19 | — | — | EP | claimed |
| US-20240385193-A1 | USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER | GLYCANOSTICS S.R.O. (SK) | 2024-11-21 | — | — | US | claimed |
| US-20240377402-A1 | GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER | GLYCANOSTICS S.R.O. (SK) | 2024-11-14 | — | — | US | claimed |
| WO-2024223815-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | INBIOSE N.V. (BE) | 2024-10-31 | — | — | WO | claimed |
| US-20240361330-A1 | STANDARD FOR GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2024-10-31 | — | — | US | claimed |
| EP-4396583-A1 | USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER | Glycanostics s.r.o. (SK) | 2024-07-10 | — | — | EP | claimed |
| WO-2023198337-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2023-10-19 | — | — | WO | claimed |
| EP-4253958-A2 | MEANS AND METHODS FOR GLYCOPROFILING OF A PROTEIN | Glycanostics s.r.o. (SK) | 2023-10-04 | — | — | EP | claimed |
| EP-3775909-B1 | MEANS AND METHODS FOR GLYCOPROFILING OF A PROTEIN | GLYCANOSTICS S R O (SK) | 2023-05-10 | — | — | EP | claimed |
| WO-2023041565-A1 | USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER | GLYCANOSTICS S.R.O (SK) | 2023-03-23 | — | — | WO | claimed |
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | INBIOSE N V (BE) | 2026-05-21 | — | — | US | disclosed |
| US-20260132407-A1 | VIVO SYNTHESIS OF SIALYLATED COMPOUNDS | INBIOSE N V (BE) | 2026-05-14 | — | — | US | disclosed |
| EP-4731778-A2 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-20220117984-A1 | METHODS OF USING HUMAN MILK OLIGOSACCHARIDES FOR IMPROVING AIRWAY RESPIRATORY HEALTH | ABBOTT LABORATORIES (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3980542-A1 | OPTIMAL CHROMOSOMAL INSERTION LOCI | Inbiose N.V. (BE) | 2022-04-13 | — | — | EP | disclosed |
| US-11260088-B2 | Methods for increasing growth of beneficial bacteria in the gastrointestinal tract | ABBOTT LABORATORIES (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220040212-A1 | ORAL REHYDRATION COMPOSITION WITH OLIGOSACCHARIDES | ABBOTT LABORATORIES (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132407-A1 | VIVO SYNTHESIS OF SIALYLATED COMPOUNDS | NANS, NANP, NAPRT | SELP 371/4885SELL 607/4885SIGLEC7 166/4885 |
| US-20240361330-A1 | STANDARD FOR GLYCOPROFILING OF PROTEINS | GALNT14, LGALS3BP, GALNT13 | SELP 38/4885SELL 229/4885SIGLEC7 10/4885 |
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | GALNT3, NANS, ENGASE | SELP 621/4885SELL 599/4885SIGLEC7 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.